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We have examined fetal thymic development in the trisomy 16 (Ts16) mouse, which is
considered to be a model for human trisomy 21, or Down Syndrome. The Ts16 thymus
contains 10 to 20% of the number of lymphocytes found in a normal thymus at a
comparable stage. Expression of thymocyte differentiation markers (Thy-1, CD5, CD8,
CD4, CD3, and HSA) is severely affected in Ts16 fetuses aged 14-18 gestational days.
When thymuses from 14-day Ts16 mice were cultured in vitro, these markers eventually
reached levels of expression comparable to those seen in normal thymuses in culture.
On the other hand, expression of CD44 appears to be unaffected in Ts16 thymuses in
vivo, but declines in vitro relative to normal thymuses. Reconstitution of depleted thymic
stroma with thymocytes showed evidence of defects in both developmental
compartments.
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INTRODUCTION
Human trisomy 21, or Down Syndrome (DS), is
known to affect the immune system, causing high
rates of leukemia incidence (Fong and Brodeur,
1987) and increased susceptibility to infectious
diseases (Fryers, 1986). A variety of cellular
defects has been reported in the DS immune sys-
tem, including altered circulating antibody levels
(Sassaman, 1982), decreased natural cytotoxic
activity (Montagna et al., 1988; Nair and
Schwartz, 1989), impaired T-cell responses
(Montagna et al., 1988; Raziuddin and Elawad,
1990), and altered expression of differentiation
antigens (Larocca et al., 1988; Noble and Warren,
1988; Raziuddin and Elawad, 1990). However,
the developmental origin of these cellular alter-
ations is not known.
Murine trisomy 16 (Ts16) has been proposed as
an animal model for DS. The use of this particu-
lar trisomy is based on the fact that several genes
from the region of human chromosome 21 most
important in creating the DS phenotype (Sinet et
al., 1976; Summitt, 1981; Artonarakis et al., 1989;
Rahmani et al., 1989) are shared between human
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chromosome 21 and mouse chromosome 16
(Epstein et al., 1984; Reeves et al., 1986). These
mice can be systematically produced by using a
breeding scheme involving Robertsonian chro-
mosome translocations (Gropp et al., 1975). Mice
are produced that are heterozygous for two dif-
ferent Robertsonian chromosomes, each of which
contains the chromosome of interest. When these
animals are bred with chromosomally normal
mice, their offspring may be normal, monosomic,
trisomic, or combined monosomic/trisomic. The
monosomics and monosomic/trisomics die by
day 8 of gestation (Gropp, 1982; Epstein, 1988),
leaving only trisomic and normal mice. Ts16 mice
can survive until birth, but die within a few
hours (Miyabara et al., 1982).
The first observation to indicate that Ts16
affects the immune system was that the thymus is
only about 20% of normal size throughout devel-
opment (Epstein et al., 1985). Herbst et al. (1982)
examined the ability of fetal liver cells from mice
carrying various trisomies to repopulate lethally
irradiated animals. They found that, although
some trisomies had no apparent effect on this
stem-cell population, Ts16 caused significant
reductions in repopulation. This suggests
impaired development of Ts16 lymphocytes even
before they reach the thymus or other adult
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lymphoid organs. Cox et al. (1984) fused Ts16
and normal embryos at the 8-12 cell stage. In
nearly all organs of the resultant chimeras, tri-
somic and normal cells were present in approxi-
mately equal numbers as measured by glucose
phosphate isomerase isozyme analysis. In the
thymus and placenta, however, Ts16 cells were
markedly deficient as compared to control chim-
eras made with normal littermates or to other tis-
sues of the same animal. This is further evidence
for a primary defect in cells of the immune sys-
tem in Ts16 mice. Studies looking directly for
defe.cts in Ts16 lymphoid stem cells (Epstein et
al., 1985) have shown reductions in stem cell
numbers as measured in various in vitro and in
vivo assays. However, these differences were pri-
marily observed on a per animal basis and could
be attributable to the overall smaller size of the
trisomic fetus. More recently, a flow cytometric
study (Berger and Epstein, 1989) has indicated
developmental retardation in the Ts16 thymus.
Decreased expression of T-cell markers on Ts16
thymocytes was observed, and extended organ
culture of trisomic thymic rudiments resulted in
the production of cells that were closer to normal
thymocytes in their phenotypes.
This study was carried out in order to examine
the effects of Ts16 on some of the characteristic
events of T-cell development. The expression of
many of the T-cell antigens was examined by
flow cytometry, including multiparameter analy-
sis to look for effects on particular subsets of
cells. The Ts16 thymus was also grown in organ
culture to allow study of the thymocytes after a
longer period of development. Finally, thymus
reconstitution was used in an effort to determine
whether the observed thymic defects were due to
defects in the lymphocytes or the thymic stroma.
RESULTS
Difference in Growth of Normal and Ts16
Thymuses
Consistent with previous reports (Epstein et al.,
1985), the Ts16 thymus contains fewer thymo-
cytes than normal throughout development
(Table 1). There may be. a small difference in the
rate of thymic growth, but a greater part of the
difference in size could be attributed to a deficit
in cell number from the beginning of thymus
development. This can be seen most clearly by
examining the proportion of the cell numbers
seen in normal versus trisomic thymuses
throughout gestation (Table 1, last column). This
indicates that the Ts16 thymus is initially
colonized by fewer cells, with growth after this
nearly paralleling that seen in normal animals.
Thymuses removed at 14 gestational days (gd)
and cultured in vitro also show a deficiency in the
number of lymphocytes. Growth in culture is
also parallel to that of normal thymuses, at least
through 6 days in vitro. At 9 days, while most of
the Ts16 cultures continue to increase in cell
number, some (about 25%) have begun to decline
in size. (This accounts for the high variability in
cell number seen in these cultures.) Virtually no
live cells can be recovered from Ts16 thymuses
cultured for 12 days or longer.
Expression of Thymocyte Differentiation
Markers
In normal mice, expression of Thy-1 (Table 2)
TABLE
Number of Lymphocytes Obtained from Normal and
Ts16 Thymuses
Age and n Mean S.D. p Proportion
genotype cell no. Ts16/normal
In vivo
13 Nor. 32 1.0x104 6.7x103
Tri. 26 2.3x103 1.6x103 <0.01 0.23
14 Nor. 32 4.9x104 4.0x104
Tri. 27 1.2x104 1.4x10 <0.01 0.24
15 Nor. 36 2.5x105 1.4x105
Tri. 35 4.6104 4.5104 <0.01 0.18
16 Nor. 23 9.4105 3.6x104
Tri. 26 1.1x105 7.8x104 <0.01 0.11
17 Nor. 18 3.8106 3.2106
Tri. 15 6.4x105 1.4106 <0.01 0.19
18 Nor. 15 9.5106 4.9106
Tri. 14 8.8x10 5.3x105 <0.01 0.09
In vitro
3 Nor. 17 2.1x105 1.2x10
Tri. 18 3.8104 2.4x104 <0.01 0.19
6 Nor. 12 6.3105 2.0x10
Tri. 12 2.0x10 1.5x105 <0.01 0.32
9 Nor. 18 6.5x10 3.7x105
Tri. 16 1.5x105 1.5x10 <0.01 0.23
"Age indicated for cultured thymuses is the number of days in culture.
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rises from 13 to 16 gd, after which close to 100%
of the cells express this marker through the
remainder of fetal development. In the trisomic
animals, a similar pattern is seen, but the pro-
portion of cells expressing Thy-1 is lower. A
small population of thymocytes (about 5%)
remains Thy-1- even at 18 gd. Different results
are seen in vitro, where essentially 100% of both
normal and trisomic thymocytes label with Thy-1
after 3 or more days of organ culture.
Entry of Ts16 thymocytes into the more mature
cell populations identified by expression of CD5,
CD8, and CD4 appears to be delayed when com-
pared to the course of normal development. This
is particularly clear in the case of CD5 (Table 2).
Expression of this antigen is close to normal
levels early in development, but the increase of
expression seen in normal thymuses beginning at
16 gd is delayed by a day in the Ts16 thymus and
the proportion of cells expressing the antigen
remains lower than normal throughout develop-
ment. CD5 expression does catch up to normal
after 9 days in organ culture. In vivo, double labe-
ling with CD8 and CD4 shows a similar develop-
mental retardation (Table 3; Fig. 1). The double-
negative cell population remains much larger
than in normal thymuses throughout develop-
ment, and still is markedly enlarged at 18 days.
The inverse pattern is seen in the double-positive
subset, which does not show any substantial
increase until the end of development. These sub-
sets do approach normal levels after 9 days of
organ culture. A different pattern, however, is
seen for CD8//CD4- cells. In normal mice, cells of
this phenotype (presumably representing the
immature CD8-positive subset) appear at gd 16
and decline rapidly after that. In trisomic ani-
mals, these cells appear a day later than normal,
and still represent a substantial proportion of the
thymic population at 18 gd. In culture, the Ts16
thymuses also show a larger proportion of cells
in this subset than do normal thymuses. This
TABLE 2
Expression of Thy-1, CD5, and CD44 During Embryonic Development and in Organ Culture
Age and Thy-1
genotype F/b % positive
+S.D:
CD5 CD44
p n % positive p n % positive p
+S.D5 +S.D.
In vivo
13 Nor.
Trl.
14 Nor.
Tri.
15 Nor.
Tri.
16 Nor.
Tri.
17 Nor.
Tri.
18 Nor.
Tri.
9 53.0+20.3
5 2214+19.8
8 68.4+14.6
6 43.0+23.7
5 96.5+2.5
5 81.6+10.0
5 96.0+4.9
5 86.2+13.1
5 93.5+7.9
5 84.4+11.3
7 99.3+0.5
4 89.2+8.1
In vitro
3 Nor. 3 97.2+0.8
Tri. 4 92.9+6.0
6 Nor. 2 97.9+2.2
Tri. 2 98.8+0.4
9 Nor. 2 97.5+0.9
Tri. 2 97.2+1.3
6 17.3+21.2 4 85.8+39.3
<0.05 4 13.7+13.7 4 39.3+23.1 <0.01
4 20.1+6.3 5 54.1+23.2
<0.05 4 22.1+14.4 5 67.8+9.5
5 21.5+3.6 7 47.4+9.9
<0.05 4 18.8+3.1 5 55.0+10.4
5 53.9+14.4 5 24.1+7.1
5 16.5+8.7 <0.01 5 37.1+18.7
4 74.6+8.1 4 25.4+14.3
3 30.6+21.5 <0.05 4 18.5+7.7
6 91.4+3.6 4 8.3+8.6
<0.01 6 48.2+27.5 <0.01 4 4.8+2.0
4 57.6+2.9 4 43.7+13.3
4 22.6+6.6 <0.01 4 40.5+3.2
4 81.2+3.0 5 35.5+14.7
4 62.1+2.9 <0.01 5 11.8+4.9 <0.01
4 82.4+1.7 5 43.5+10.9
4 81.4+4.2 4 18.6+10.8 <0.05
aAge indicated for cultured thymuses is the number of days in culture.
bn=number of thymuses tested.
cS.D.=standard deviation.
aThese values significantly different (p<0.05) according to the Mann-Whitney U test.218 J.L. EWART AND R. AUERBACH
may indicate a partial block to thymocyte devel-
opment that prevents or slows the progress of
cells from the CD8//CD4- subset to the
CD8//CD4+ subset. CD8-/CD4
/ cells, which pre-
sumably represent the most mature cells in the
thymus, are first evident after 6 days in culture
and, in contrast to the other subsets, show little
difference between normal and Ts16 thymuses.
In contrast, there is no consistent difference
between normal and Ts16 thymocytes in the pro-
portion of cells expressing CD44, a marker for
immature thymocytes (Table 2). In thymuses cul-
tured in vitro, the percentage of cells expressing
CD44 declines more rapidly in trisomic than in
normal thymuses.
Expression of T-cell Receptors
A smaller proportion of cells expressed CD3 in
Ts16 as compared to normal thymuses (Table 4),
again with some catching up in vitro. CD3
/ cells
in the thymus fall into two groupsmCD8-/CD4
cells, which appear early in thymus develop-
ment, and CD8/CD4 single-positive cells, which
arise later. The results with CD44 indicated that
early stages of thymocyte differentiation were
not affected by the trisomy. Therefore, we were
interested to know whether Ts16 affects both
CD3-expressing subsets or only the later-appear-
ing one. To examine this question, thymocytes
were triple-labeled with CD8, CD4, and CD3. The
proportion of cells expressing CD3 in the various
CD8/CD4 subsets was the same in normal as in
Ts16 thymuses in virtually all cases. However,
the Ts16 CD8-/CD4-cells do show a small but
consistent decrease in the percentage labeling
with CD3 (Table 4). This indicates that pro-
duction of the CD8-/CD4-/CD3
/ population,
which includes cells expressing the ,/ T-cell
receptor, is affected by Ts16, although perhaps
not as much as the populations expressing CD8
and CD4.
To test this more directly, thymocytes were
labeled with monoclonal antibody 536, which
detects the V//3 T-cell receptor chain. As shown in
Table 4, the percentage of cells labeled with 536 is
greater than or equal to that seen in the normal
thymus throughout development. There is no
indication of a delay in the onset of expression of
this antigen, although the decline in this popu-
TABLE 3
Percentage of Cells in CD8/CD4 Defined Subsets During Embryonic Development and in Organ Culture
Age and n Subset
genotype CD8*/CD4 CD8-/CD4- CD8//CD4- CD8-/CD4
Mean % pb Mean % pb Mean % pb Mean % pb
+S.D. +S.D. +S.D. +S.D.
In vivo
15 Nor. 5 0.9+0.5 93.9+2.6 2.9+2.2 2.3+0.6
Tri. 5 2.5+1.4 <0.05 90.9+6.3 2.9+1.7 3.9+4.2
16 Nor. 5 28.7+9.9 56.4+10.9 11.5+2.9 3.4+2.9
Tri. 6 3.7+3.4 <0.1 89.9+5.4 <0.01 315+2.1 2.9+0.8
17 Nor. 4 62.7+8.3 28.0+7.5 6.1+3.2 3.3+0.7
Tri. 4 7.3+7.0 <0.01 74.2+11.1 <0.01 15.2+3.8 <0.01 3.3+1.7
18 Nor. 7 79.0+8.1 12.8+6.4 5.8+2.7 2.5+1.0
Tri. 5 31.3+27.7 <0.01 52.8+36.9 <0.05 13.5+10.5 <0.1 2.3+1.8
In vitro
3 Nor. 5 42.8+7.6 37.0+8.1 17.7+2.8 2.5+0.8
Tri. 5 3.8+1.5 <0.01 73.0+4.8 <0.01 21.4+4.0 1.8+0.8
6 Nor. 4 66.9+6.0 11.9+3.8 8.3+2.7 13.0+5.1
Tri. 4 51.8+1.6 <0.05 19.4+1.7 <0.01 19.4+2.6 9.4+2.7
9 Nor. 5 52.5+13.4 21.2+12.3 14.4+6.3 12.0+5.8
Tri. 5 46.6+17.7 24.8+16.9 18.8+4.7 9.8+2.7
’Age indicated for cultured thymuses is the number of days in culture, with thymuses for cultures taken from 14-gd embryos.
bp values derived from Student’s test.
’These values not significantly different (p>0.05) according to the Mann-Whitney U test.THYMUS DEFECTS IN THE TRISOMY 16 MOUSE 219
lation near the end of development is apparently
slowed.
Thymic Reconstitution Experiments
Having shown that Ts16 significantly affected the
differentiation of thymocytes, we were interested
A B
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FIGURE 1.
CD8 CD8
Expression of CD8 and CD4 on (A) 16-gd normal,
(B) 16-gd Ts16, (C) 18-gd normal, (D) 18-gd Ts16, (E) 3-day
cultured normal, (F) 3-day cultured Ts16, (G) 9-day cultured
normal, and (H) 9-day cultured Ts16 thymocytes. Data are
plotted on a log scale with a 4-decade range, with CD8
expression (FITC label) on the horizontal axis and CD4
expression (PE label) on the vertical axis.
in determining whether the defect lay primarily
in the lymphocytes themselves or in the thymic
stroma. The technique of thymic reconstitution
(Jenkinson et al., 1982) was used to address this
question. In order to distinguish donor from host
lymphocytes, cells or stroma from C57B1/Ka
mice (referred to hereafter as Ka), which carry
the Thy-l.1 allele, were combined with the cells
or stroma from the Ts16 mice or their normal lit-
termates. These latter express Thy-l.2 that can be
distinguished from Thy-l.1 by labeling with
specific antibodies. In all subsequent exper-
iments, a sample of lymphocytes from each
reconstituted thymus was labeled with biotinyl-
ated Thy-l.2 antibody (rat IgG) followed by
phycoerythrin-conjugated avidin as well as with
Thy-l.1 antibody (mouse IgM) followed by fluor-
esceinated antimouse IgM. Any thymus showing
a significant number of host-type cells (>50%)
was excluded from consideration. In order to
determine whether Ts16 cells or-stroma produced
lymphocytes that differed from normal, the cells
derived from reconstituted thymuses were lab-
eled with antibodies to CD8 and CD4. These mar-
kers were chosen because they showed the
greatest and most consistent differences between
normal and Ts16 thymuses. When cells from Ts16
animals and their normal littermates were used
to reconstitute thymic lobes, equal numbers of
cells were used to eliminate possible effects on
development due to differences in the number of
cells obtained from normal and Ts16 tissues.
Thymocytes from 14 gd fetal mice were used to
reconstitute depleted thymic rudiments. The
reconstituted thymuses were cultured for 6 days,
then labeled with antibodies to CD8 and CD4,
and analyzed by flow cytometry. Results are
shown in Table 5 and Fig. 2. When Ka thymuses
were reconstituted with thymocytes from Ts16
animals or their normal littermates, lymphocytes
derived from trisomic cells show a significantly
higher percentage of cells in the immature dou-
ble-negative population and a lower percentage
in the CD8//CD4 subset, indicating that the Ts16
thymocytes were delayed in their maturation
even in a normal stromal environment.
Next, the reverse experiment was performed,
in which Ka thymocytes were seeded into thymic
lobes from Ts16 mice and their normal lit-
termates. Again, some difference between normal
and Ts16 thymic stroma was seen, but less than
in the first experiment. Ts16, therefore, must220 J.L. EWART AND R. AUERBACH
affect the ability of the thymic stroma to support
the development of thymocytes, but this defect
may not be as great as that seen on the lym-
phocytes.
The numbers of cells derived from these recon-
stituted thymuses were also compared (Table 5).
Although there was not a high level of signifi-
cance because variability Was very high, the Ts16
cells seeded into normal stroma did show some
tendency to yield fewer cells after culture,
whereas the normal cells in Ts16 stroma did not.
This lends further support to the hypothesis that
the lymphocytes are more affected than the thy-
mic stroma by Ts16.
DISCUSSION
These studies show defects in cell number and
differentiation during the development of the tri-
somy 16 thymus. The trisomy causes a reduction
in cell number throughout development and
adversely affects the ability of the thymus to sur-
vive in organ culture. The appearanc6 of mature
thymocyte subsets is delayed, but the early
stages of thymus development are less affected.
Thymic reconstitution experiments indicate that
Ts16 affects both the lymphocytes and the thymic
stroma.
It had already been established (Epstein et al.,
1985) that the Ts16 thymus is considerably
smaller than that of the normal mouse through-
out fetal development. There was some question
as to whether this difference resulted from
slower proliferation of thymocytes or fewer stem
cells entering the thymus. The results presented
here indicate that the latter explanation is the
correct one, as the normal and trisomic thymus
are already significantly different in cell number
at 13 days and this difference increases only
slightly during development, although there may
be some decline of the Ts16 thymus at 18gd
when some of the trisomic fetuses appear to be
dying. In culture, however, the Ts16 thymocytes
do not grow as well as their normal counterparts,
which may indicate that they are more sensitive
to environmental changes or that they are more
limited than normal cells in the length of time
TABLE 4
Percentage of Thymocytes Expressing CD3 and V//3 During Embryonic Development and in Organ Culture
Age and CD3 on total cells CD3 on CD8-/CD4- cells V on total cells
genotype
n % positive pb n % positive pb n % positive pb
+S.D. +S.D. +S.D.
In vivo
14 Nor. 3 0.7+0.4 N.D. 6 0.6+0.5
Tri. 3 2.5+3.8 N.D. 6 1.7+1.1 <0.05*
15 Nor. 5 7.0+2.1 N.D. 2 2.2+0.3
Tri. 6 1.9+1.3 <0.01 N.D. 2 1.5+0.8
16 Nor. 5 6.8+4.3 4 21.9+10.5 3 1.6+0.4
Tri. 5 3.1+0.6 4 14.5+8.0 3 1.1+0.9
17 Nor. 4 7.8+2.2 4 9.0+2.2 4 0.9+0.2
Tri. 4 6.1+2.9 4 8.5+3.0 4 3.9+1.3 <0.01
18 Nor. 4 23.0+7.8 5 13.5+1.2 6 0.4+0.1
Tri. 4 12.2+3.1 <0.05 5 12.3+0.9 5 2.0+0.8 <0.01
In vitro
3 Nor. 4 23.3+8.0 6 11.5+4.8
Tri. 4 13.1+2.9 <0.1 7 24.2+10.6
6 Nor. 4 27.1+7.8 4 38.3+7.4
Tri. 4 18.7+5.0 4 26.5+12.1
9 Nor. 4 34.8,+7.4 3 39.4+8.3
Tri. 4 30.9+9.9 4 29.3+10.5
<0.01
aAge indicated for cultured thymuses is the number of days in culture, with thymuses for cultures taken from 14-gd embryos.
bp values derived from Student’s test.
CThese values not significantly different (p>0.05) according to the Mann-Whitney U test.THYMUS DEFECTS IN THE TRISOMY 16 MOUSE 221
TABLE 5
Cell Number and CD8/CD4 Expression of Reconstituted Thymuses
Host thymus Ka Ka Rb normal
Source of lymphocytes Rb normal Rb Ts16 pC Ka
Rbb Ts16
Ka
n 3 4 3 3
Cell number 1.4xl0 4.5xl0 <0.1 3.5xl0
+S.D. +8.0x10 +2.1x10 +2.1x10
5.4104
+5.0X104
Mean% Mean% Mean%
+S.D. +S.D. +S.D.
CD8//CD4 10.4+2.7 9.8+1.2 9.1+1.9
CD8-/CD4- 52.5+3.3 71.6+3.8 <0.01 52.7+3.6
CD8//CD4- 32.5+6.9 14.7+3.8 <0.01 34.3+3.7
CD8-/CD4 4.6+1.0 4.0+2.4 3.9+1.5
Mean%
+S.D.
7.3+2.4
63.1+4.3
25.9+9.0
3.7+2.3
<0.05
aThymocytes taken from 14-gd embryos and reconstituted thymuses cultured for days.
bRb indicates animals derived from using Rb(6.16/16.17) male.
Cp values derived from Student’s test.
dCell numbers determined for only two of these samples.
A B
C
CD8 CD8
FIGURE 2. Expression of CD8 and CD4 on cells from
depleted thymuses reconstituted with 14-day thymocytes and
cultured for 6 days. (A) Ka thymuses seeded with normal
thymocytes. (B) Ka thymuses seeded with Ts16 lymphocytes.
(C) Normal thymuses seeded with Ka lymphocytes. (D) Ts16
thymuses seeded with Ka lymphocytes. Data are plotted on a
log scale with a 4-decade range, with CD8 expression (FITC
label) on the horizontal axis and CD4 expression (PE label) on
the vertical axis.
they can survive or the number of divisions they
can undergo.
When Ts16 thymocytes were labeled with anti-
bodies to markers characteristic of mature T cells,
the results generally indicated developmental
retardation. The patterns of staining with CD5,
CD8, and CD4 were particularly clear in this
regard (Tables 2 and 3; Fig. 1). Expression of each
of these markers showed a delay of 1-2 days
throughout fetal development, and cultured thy-
muses were able to "catch up" to their normal
counterparts. This pattern of retardation also
tends to be true for CD3 expression (Table 4).
Not all differentiation markers show such a
clear-cut pattern of developmental retardation.
Thy-1 is expressed on virtually 100% of thymo-
cytes through most of fetal development in nor-
mal mice. In trisomic animals, expression of this
marker appears to reach a constant level of
expression at the same time as in normal thy-
muses. However, in the Ts16 mice, a small popu-
lation of nonstaining cells remains throughout
development. Interestingly, the results seen for
Thy-1 in vitro are quite different, as the Ts16 thy-
mocytes show the same high levels of expression
as in the normal thymuses. This would seem to
indicate either that a factor present in the tri-
somic animal is preventing the. maturation of
cells in the thymus, or a subset of cells that do
not express differentiation markers migrates into
the trisomic thymus in vivo after the stage at
which the thymus is removed for culture in these
experiments. The second possibility seems likely
to be true because these cultures were taken from
the animals before the second wave of precursors
is believed to migrate into the thymus (Owen and
Jenkinson, 1981).222 J.L. EWART AND R. AUERBACH
These results largely corroborate those of
Berger and Epstein (1989). They examined
expression of Thy-1, CD4, CD8, CD5, and CD3
during fetal development with largely similar
results. The results seen in thymic organ culture,
however, were somewhat different, which may
be because thymuses were taken for culture
beginning at 15 or 17 gd rather than 14 gd. Data
were obtained from thymuses cultured for as
long as 17 days (beginning at 15 gd), which may
indicate that later stem-cell immigrants have
entered the Ts16 thymus at this point and are
more able to survive in culture than the first-
wa;e cells present in the 14-day thymus. Alterna-
tively, it may be that the smaller size and
reduced cellularity of the Ts16 thymus are the
important factors in its lessened ability to survive
in vitro and that by allowing one more day of
growth in vivo, it is possible to circumvent this
problem. Expression of CD3, CD4, and CD8 did
catch up to normal in-cultured thymuses in both
studies.
Antigens expressed only on immature or early
appearing thymocyte subsets, such as CD44 and
V3, are apparently less affected by Ts16. The fact
that the loss of CD44 expression seems com-
pletely unaffected (Table 2) supports the idea
that this is a very early event in thymocyte differ-
entiation, as it seems unlikely that cells already
delayed in their, development (by criteria such as
the expression of’, for example, Thy-1) would
then undergo a later developmental event with
normal timing. Because the early expression of
both V3 and CD3 also appear to be unaffected,
the early ,/3 cells (and, possibly, the dendritic
epidermal cells derived from them; Havran and
Allison, 1990) may be completely normal in Ts16
mice.
There are two possible explanations for the
relative lack of effect on more immature thymo-
cyte subsets. One is that development is able to
proceed normally up to a certain point, but is
delayed after this, possibly due to some specific
regulatory mechanism altered by the trisomy.
The other is that, if development is really taking
place at a slower rate (as opposed to occurring
with a delay compared to normal), it ’would be
expected that there would be a greater disparity
between the timing of.later events than that of
earlier ones. Although it is difficult to distinguish
between these possibilities, the lack of effect on
CD44 expression would indicate that there is an
early stage unaffected by Ts16. The fact that there
is no more difference between the normal and tri-
somic thymuses in expression of this marker at
18 gd than there is at 14 gd makes it more likely
that the trisomy affects a particular point in thy-
mocyte development.
In addition to the defect seen in late stages of
maturation of the Ts16 thymus there is evidence
for effects of the trisomy on stem-cell prolifer-
ation and/or survival. Because the Ts16 thymus
contains fewer cells from the beginning of its
development, there must be a defect that affects
the proliferation or formation of hematopoietic
stem cells before they enter the thymus. The
decline in cell number after long-term culture of
the Ts16 thymus, as well as the decrease in the
number of CD44-expressing cells seen in cultured
thymic lobes, may indicate that there is also a
problem in the ability of thymic stem cells to sur-
vive in organ culture.
The thymic reconstitution experiments were
performed to address the question of stem-cell
competence more directly, but the results
obtained were somewhat ambiguous. Ts16 lym-
phocytes did seem to be impaired compared to
normal in their ability to differentiate in a normal
thymic stroma. There was also some indication of
an effect of Ts16 on the stroma that may be
impaired in its ability to support thymocyte dif-
ferentiation. It is possible that the relatively small
differences seen in reconstituted thymuses as
compared to untreated cultured thymuses were
because the reconstitution was performed with
equal numbers of cells for normal and Ts16 tis-
sues. In normal thymic development, lympho-
kines produced by the thymocytes themselves
may be important for T-cell development
(Jenkinson et al., 1987; Skinner et al., 1987;
Carding et al., 1989), so it is possible that the
problems seen in the Ts16 thymus are due par-
tially to an insufficient number of cells to pro-
duce the required concentration of these factors.
It is difficult to relate these results directly to
the immune defects seen in Down Syndrome, as
few studies of DS have looked at fetal tissue. The
expression of some differentiation markers on
the DS fetal thymus has been examined
(Cossarizza et al., 1989). No differences between
normal and DS thymuses were seen, but only two
cases of each type were examined and the varia-
bility between them was very high. Another
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number of young children with DS (Larocca et
al., 1988) did find significant decreases in the
expression of several thymocyte antigens, includ-
ing CD3, CD4, and CD8.
Of course, it would be most important if the
Ts16 phenotype proved to have any relevance to
the clinical problems of the DS immune system.
If immature thymocytes (i.e., those not express-
ing differentiation antigens) persist in DS as they
do in Ts16, they may be involved in the develop-
ment of leukemia. These thymocytes could not
account for all of the proliferative abnormalities
seen in DS, as many different types of lympho-
cytic and nonlymphocytic leukemias are seen
(Fong and Brodeur, 1987). It would be of interest
to determine whether other types of hemato-
poietic cells show similar developmental delays
in Ts16 and/or DS, which could indicate that
various types of immature hematopoietic cells
exist and have the potential to become leukemoid
in DS. The observed defects in T-cell functions
seen in DS probably could not be studied in cells
derived directly from Ts16 mice, because mature
CD4’ and CD8 single-postive cells are not pro-
duced by the time these animals die. However,
these cells are produced in organ cultures, which
could be used as a source of material to test the
functional capacities of Ts16 T cells. In addition,
such cultures could be used for testing the effects
of lymphokines or other factors on the differen-
tiation of Ts16 cells.
The usefulness of any of these approaches to
relating the phenotype of the Ts16 mouse to the
clinical manifestations of DS is limited because
the mice do not survive past birth. There are
several approaches that may be useful in circum-
venting this problem. One already mentioned is
that of making chimeric mice by fusing Ts16 and
normal blastocysts. Studies using this method
(Cox et al., 1984; Gearhart et al., 1986) have indi-
cated that Ts16 hematopoietic cells are at a com-
petitive disadvantage compared to normal cells
in these chimeras, indicated by a deficiency of
Ts16 cells in the thymus and a postnatal decrease
in Ts16 cells in the blood. This fact, of course,
makes it difficult to use such animals to study the
functions of Ts16 immune-system cells, altfiough
the use of appropriate genetic markers (such as
immunologically distinct alleles of thymocyte
antigens) may make it possible to distinguish
cells from the Ts16 blastocyst fusion partner by
flow cytometry.
An alternative to the use of chimeras is to gen-
etically alter mice so that they carry only parts of
the chromosome in extra copies. Such animals
may be expected to have fewer defects than those
carrying the entire extra chromosome and there-
fore to survive longer. In addition, this approach
would avoid the problem of how murine genes
present on chromosome 16 but not shared with
human chromosome 21 might affect development
of Ts16 mice or cells derived from them. The
human genomic sequence of SOD-l, one of the
genes present on both mouse chromosome 16
and human chromosome 21, has been injected
into mouse eggs to produce transgenic mice
(Epstein et al., 1987). These mice express
increased levels of the enzyme, but appear
grossly normal. However, they do display alter-
ations in neuromuscular junctions of the tongue
similar to those seen in DS (Avraham et al., 1988).
These results suggest that it may be possible to
mimic specific phenotypes of DS in mice trans-
genic for genes found on human chromosome 21.
However, they also suggest that the presence of
one such extra gene is not enough to produce a
broad spectrum of the phenotypic alterations
associated with DS. A more accurate model
would be a mouse carrying an extra copy of the
entire chromosome segment responsible for the
DS phenotype. It may be possible to create such
animals by the injection of microdissected human
chromosome segments into fertilized eggs to pro-
duce "transomic" mic6 (Richa and Lo, 1989). If
viable mice carrying this portion of the human
chromosome could be produced and were viable,
they would be ideal candidates for a viable DS
model in mice.
MATERIALS AND METHODS
Mice
Strains Rb(6.16)24Lub and Rb(16.17)8Lub, carry-
ing Robertsonian translocation chromosomes,
were obtained from Jackson Laboratories (Bar
Harbor, Maine) and maintained as breeding
stocks in our laboratory. Females of strain
C57B1/6 were obtained from Jackson or bred in
our laboratory. Breeding males were produced
by crossing the two Robertsonian strains. These
males were caged with C57B1/6 females and224 J.L. EWART AND R. AUERBACH
timed pregnancies were obtained by checking for
vaginal plugs (plug day=0).
Reagents
Monoclonal antibodies to Thy-l.2 (fluores-
ceinated or biotinylated), CD5 (fluoresceinated),
CD8 (fluoresceinated or biotinylated), and CD4
(phycoerythrin conjugated), as well as allophyco-
cyanin (APC)-conjugated avidin were obtained
from Becton-Dickinson (Mountain View,
California). Phycoerythrin-conjugated avidin
was obtained from Vector (Burlingame,
California). Monoclonal antibodies to CD44
(1M7.8.1; Trowbridge et al., 1982), from Robert
Hyman, Salk Institute, (San Diego, California);
CD3 (145-2Cll; Leo et al., 1987), from Jeffrey A.
Bluestone, National Cancer Institute, (Bethesda,
Maryland); and Thy-l.1 (TIB 100, American Type
Culture Collection) were produced in our labora-
tory as culture supernatants from James P. Alli-
son. Fluoresceinated secondary reagents used
were goat antirat IgG and goat antimouse IgM
(TAGO, Inc., Burlingame, California) and goat
antihamster IgG (Cappel, Organon Teknika
Corp., West Chester, Pennsylvania).
incubated for 2-12 hr (longer times were neces-
sary for tissues from older fetuses) in RPMI+10%
FBS+0.3 tg/ml colcemid+antibiotics+5/g/ml
LPS. They were then treated with 0.075 M KC1,
fixed in 3:1 methanol:acetic acid, and stored at
4 C. Suspensions were then dropped onto a
slide, air dried, and stained with Giemsa (diluted
1:50). Slides were viewed under immersion oil on
a Zeiss microscope at 1250x magnification.
Flow Cytometric Analysis
Thymuses were manually dissociated with fine
forceps, filtered through a 15-t Nitex filter,
counted in a hemocytometer, and resuspended in
FACS buffer (PBS+1% BSA+0.1% sodium azide).
Cells were incubated with antibody, lectin, or
avidin for 30 min. When more than one labeling
step was required, cells were washed with an
excess of FACS buffer between incubations.
The cells were analyzed on a Becton-Dickinson
FACStar Plus flow cytometer. Fluorescein and
phycoerythrin were excited with a 488-nm argon
laser line and APC with a 647-nm krypton laser
line. Dead and nonlymphocytic cells were
excluded on the basis of forward light scatter.
Generating Trisomic Animals
Pregnant females were sacrificed and fetuses ten-
tatively scored as’normal or trisomic based on
edema and condition of eyelids (trisomics
develop severe edema and their eyes usually do
not close). Tissues to be used were dissected from
all putative trisomics and from an equal number
of normal littermates to use as controls.
Karyotyping
Liver cells (13 gd or older animals) or yolk sac
cells (12 gd) were used for karyotyping to verify
the visual diagnosis. Karyotypes were attempted
for all animals used, but occasionally samples
were lost or mitotic cells were not found in the
samples (This latter problem occurred most com-
monly in fetuses from later gestational stages,
when Ts16 animals are very easy to distinguish
by phenotype.) Nearly all (>90%) of animals
were karyotyped, and. the results always con-
firmed the diagnoses based on phenotype.
Karyotyping was performed according to stan-
dard methods (Hogan et al., 1986). Cells were
Thymus Culture
Thymus culture was performed according to a
method derived from that of Jenkinson et al.
(1987) and modified in this laboratory. Culture
dishes were prepared by placing 0.8-t Nuclepore
filters (Nuclepore, Pleasanton, California) on
slices of Gelfoam gelatin sponges (Upjohn, Kala-
mazoo, Michigan) (approx. 1 mm thickness) in
35-mm tissue-culture dishes. (Both sponges and
filters were preboiled twice.) 1 ml of culture
medium (RPMI+10% FBS+antibiotics+0.01 M
HEPES+0.0035% fl-mercaptoethanol) was added
to each dish. Thymic lobes were dissected ster-
ilely from fetuses of 14 gestational days (gd),
placed on the filters, and incubated at 37C with
5% CO2 for the desired length of time.
To reconstitute thymuses, cultures were set up
as before except that the culture medium con-
tained 1.35 mM deoxyguanosine (dGuo), which
kills lymphocytes while leaving the thymic
stroma intact (Jenkinson et al., 1982). After 3 days
in culture, these thymuses were washed exten-
sively in medium without dGuo. Thymocytes
were prepared by manual dissection as describedTHYMUS DEFECTS IN THE TRISOMY 16 MOUSE 225
for flow cytometry. These cells were counted
with a hemocytometer and adjusted to the
desired cell concentration. Cell suspensions
obtained by these methods were placed in wells
of a Terasaki plate (30 fll per well). One depleted
thymic lobe was added to each well, and these
were cultured as hanging drops for 24 hr. After
this time, the thymuses were transferred to filters
and cultured as described before.
Data Analysis and Statistics
Flow cytometric data analysis was performed
using the Becton-Dickinson Disp4 and Disp2d
programs. In order to determine the percent posi-
tive of single-labeled samples versus controls,
gates were set based on control histograms and
applied to the labeled samples. The corrected
percent positive was calculated according to the
following formula:
% labeled=100x
% positive (experimental)-% positive (control)
100-% positive (control)
Data in the tables are given as the mean plus or
minus the standard deviation, with p values (for
the difference betweel normal and trisomic thy-
muses of the same age and experimental
treatment) determined by Student’s t-test. Due to
the inherent variability of results, the data were
also examined using the Mann-Whitney U test as
a check on the validity of the statistical analysis.
In nearly all cases (exceptions are marked in the
tables), differences determined to be significant
at the 0.05 level by the test were also significant
by the Mann-Whitney U test. p values are only
shown for cases in which p<0.1.
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